Rapid proliferation of E. coli is possible! Reduction of BSE/TSE risk!
Select Alternative Protein Source (APS) medium is an excellent versatile growth medium that serves as a substitute for traditional animal component-based media suitable for the subculturing and maintenance of Escherichia coli (E. coli) in molecular genetic processes. It is made from non-animal components, taking into account the risk of Bovine Spongiform Encephalopathy (BSE). 1. Rapid growth of E. coli It provides vitamins and amino acids that enhance the metabolism and growth of E. coli through soybean peptone and yeast extract, as well as increase plasmid yield. 2. Reduction of BSE/TSE risk By using non-animal-derived raw materials, it minimizes the risk of Bovine Spongiform Encephalopathy.
Inquire About This Product
basic information
Composition (per 1L of purified water) Soybean hydrolysate .......................... 2.5 g Yeast extract .................................... 12.5 g Sodium chloride ................................ 5.0 g pH 6.6 - 7.1
Price range
P1
Delivery Time
P2
※The delivery time may vary depending on the quantity, so please feel free to contact us.
Applications/Examples of results
The Select Alternative Protein Source (APS) medium is an excellent versatile growth medium that serves as a substitute for traditional animal component-based media suitable for the subculturing and maintenance of Escherichia coli (E. coli) in molecular genetic processes.
Line up（1）
| Model number | overview |
|---|---|
| 292438 | BD BBL Select APS LB Bros |
Company information
BD Japan is the Japanese subsidiary of BD, one of the world's leading medical device and medtech companies headquartered in New Jersey, USA. BD aims to lead the world in medical technology, seeking new insights in the healthcare field and improving the quality of diagnosis and treatment, with the purpose of realizing "The future of healthcare for all(TM)." By developing innovative technologies and services related to patient treatment and healthcare processes, BD supports those working on the front lines of healthcare. With approximately 77,000 employees worldwide, BD staff support researchers in the development of next-generation diagnostic and therapeutic methods and strive daily to enhance the safety of healthcare professionals and the efficiency of medical practices in clinical settings. By partnering with healthcare institutions in countries around the world and addressing global priority issues, BD contributes to improving healthcare outcomes, reducing costs, increasing efficiency, enhancing safety, and promoting access to healthcare through close collaboration with its customers, the healthcare institutions.
